One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT).
Targeted protein degradation uses different types of "degrading" drugs (degraders) to force proximity between a target protein (for example, a mutated protein that contributes to the development of a disease) and the cellular machinery that directs protein degradation.
This week, the Institute for Research in Biomedicine (IRB Barcelona) and the BBVA Foundation are hosting the 39th Barcelona BioMed Conference an event in which leading figures can exchange ideas and discuss the latest advances in the field of proximity induction-based pharmacology. The “Proximity-inducing pharmacology: Targeted protein degradation and beyond” conference, co-organised by Dr. Cristina Mayor-Ruiz, from IRB Barcelona, and Dr. Georg E. Winter, from the CeMM Research Center for Molecular Medicine in Vienna (Austria), is being held in Barcelona between 22 and 24 May. Dr. Mayor-Ruiz and Dr. Winter are experts in the development of "degraders".
Institute for Research in Biomedicine - IRB Ageing is the main risk factor for the development of cancer, and the features shared by these two biological processes are increasingly evident. This week the Institute for Research in Biomedicine (IRB Barcelona) and the BBVA Foundation are holding the 38th Barcelona Biomed conference "Quantitative dynamics of aging and premalignancy". Held at the Sant Pau Art Nouveau Site on 14, 15 and 16 November, the event will be hosting 21 internationally recognized experts in the field who will present their latest breakthroughs.